Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel To Weigh Unmet Need Vs. Liver Injury With Samsca Kidney Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Risk of drug-induced injury is likely to complicate an Aug. 5 advisory committee review of Otsuka’s kidney drug tolvaptan.

Advertisement

Related Content

Tolvaptan OK Would Require Unusual Tolerance Of Drug-Induced Liver Injury
Declaring Victory: How FDA Releases REMS
FDA Could Shift Assessment Of Drug-Induced Liver Injury In Clinical Trials
FDA Open To Revising Guidance On Drug-Induced Liver Injury

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075864

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel